DT
HealthMore in Health→
HemaGuide AI matched specialist tumor board decisions in blood cancer cases
Key Takeaways
- Nature Medicine published a study on June 30, 2026 describing HemaGuide, a locally deployable AI agent for hematological malignancies.
- The system converts unstructured records into structured cases, routes them to specialized decision modes, and grounds outputs in guidelines and more than 2,000 prior tumor board cases.
- In blinded benchmarking on 45 complex cases, the study says HemaGuide improved concordance with tumor board decisions and completed workflows with a median latency of 39 seconds.
DE
DT Editorial Team··via nature.com